DCx Biotherapeutics’ vision is to develop 1st-in-class Precision Drug Conjugates (PDC’s) against underserved cancers by designing biological synergies between antibodies and payloads to be more efficacious and significantly less toxic than traditional antibody drug conjugates. DCx is harnessing internal target discovery platforms combined with deep bioinformatics and translational sciences to advance a pipeline of immune-stimulatory PDCs to improve therapeutic outcomes against genetically-defined cancers.